Association between single nucleotide polymorphisms in DNA repair genes and the efficacy of radiotherapy in nasopharyngeal carcinoma patients.
NPC
SNPs
polymorphisms
radioresistance
radiotherapy
Journal
Contemporary oncology (Poznan, Poland)
ISSN: 1428-2526
Titre abrégé: Contemp Oncol (Pozn)
Pays: Poland
ID NLM: 101233223
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
11
2022
accepted:
21
04
2023
medline:
2
6
2023
pubmed:
2
6
2023
entrez:
2
6
2023
Statut:
ppublish
Résumé
Single nucleotide polymorphisms (SNPs) in DNA repair genes are mainly correlated with the response to radiotherapy in nasopharyngeal cancer (NPC). In NPC patients, previous research has studied the association between X-ray repair cross-complementing group 1 and 3 (XRCC1 and XRCC3) polymorphisms and radio-therapeutic response. The objective of our study was to test the association between XRCC1 Arg399Gln and XRCC3 Thr241Met polymorphisms and the response to radiotherapy in the NPC Moroccan population. A total of 100 patients with NPC were genotyped for polymorphisms in XRCC1 and XRCC3 genes. The results revealed that the genotypes and alleles of both SNPs did not show any significant association with clinical stages (for XRCC1 Arg399Gln: The present study suggests that XRCC1 Arg399Gln polymorphism does not have any impact on the radio-therapeutic response in Moroccan NPC patients whereas XRCC3 Thr241Met polymorphism may act as a prognostic indicator for NPC patients treated with radiotherapy. However, studies with a larger sample are needed to confirm our results.
Identifiants
pubmed: 37266339
doi: 10.5114/wo.2023.127307
pii: 50661
pmc: PMC10230242
doi:
Types de publication
Journal Article
Langues
eng
Pagination
28-34Informations de copyright
Copyright © 2023 Termedia.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Front Oncol. 2021 Nov 29;11:635737
pubmed: 34912697
Science. 2001 Feb 16;291(5507):1284-9
pubmed: 11181991
Arch Oral Biol. 2016 Apr;64:19-23
pubmed: 26742000
Environ Sci Pollut Res Int. 2020 Dec;27(35):43786-43799
pubmed: 32740834
Signal Transduct Target Ther. 2020 May 1;5(1):60
pubmed: 32355263
Medicine (Baltimore). 2017 Nov;96(44):e8202
pubmed: 29095251
Genet Mol Biol. 2010 Oct;33(4):637-40
pubmed: 21637570
PLoS One. 2013 Oct 08;8(10):e77005
pubmed: 24116196
J Exp Clin Cancer Res. 2018 Apr 23;37(1):87
pubmed: 29688867
PLoS One. 2014 Jul 15;9(7):e101256
pubmed: 25025378
Am J Clin Oncol. 2017 Dec;40(6):535-542
pubmed: 25811296
Mil Med Res. 2018 Jun 30;5(1):20
pubmed: 29958545
Am J Transl Res. 2021 Jun 15;13(6):7382-7387
pubmed: 34306509
MedComm (2020). 2021 Jun 10;2(3):315-340
pubmed: 34766149
Radiother Oncol. 2011 Mar;98(3):387-93
pubmed: 21345510
Clin Cancer Res. 2005 Jul 1;11(13):4802-9
pubmed: 16000577
Cancers (Basel). 2021 Jul 12;13(14):
pubmed: 34298701
Radiat Res. 2008 Jul;170(1):49-59
pubmed: 18582155
Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):593-601
pubmed: 29893275
Anticancer Res. 2009 Apr;29(4):1389-93
pubmed: 19414392
Neoplasma. 2007;54(3):195-201
pubmed: 17447849
Mutat Res. 2000 Feb 16;459(1):1-18
pubmed: 10677679
Nat Rev Cancer. 2008 Mar;8(3):193-204
pubmed: 18256616
Mol Biol Rep. 2011 Apr;38(4):2849-54
pubmed: 21104022
Int J Mol Sci. 2012 Dec 05;13(12):16658-67
pubmed: 23443124
Br J Radiol. 2019 Oct;92(1102):20190209
pubmed: 31265322
Asia Pac J Clin Oncol. 2016 Mar;12(1):e125-32
pubmed: 23910235
Carcinogenesis. 2000 May;21(5):965-71
pubmed: 10783319
Front Cell Dev Biol. 2021 Feb 11;8:637435
pubmed: 33644038
EMBO J. 2004 Feb 11;23(3):670-80
pubmed: 14749735
Medicine (Baltimore). 2018 Aug;97(32):e11852
pubmed: 30095663
Asian Pac J Cancer Prev. 2015;16(2):713-8
pubmed: 25684513
Gene. 2016 May 10;582(1):33-7
pubmed: 26826460
Front Oncol. 2021 May 19;11:654784
pubmed: 34094945
Int J Med Sci. 2012;9(3):193-9
pubmed: 22408567
Protein J. 2007 Dec;26(8):541-6
pubmed: 17899335
Int J Radiat Biol. 2006 Aug;82(8):577-86
pubmed: 16966185
J Oncol. 2020 Jun 24;2020:3132786
pubmed: 32684929
PLoS One. 2013 Aug 05;8(8):e69553
pubmed: 23940523